Skip to main content
v2026.11,986 entries · CC-BY 4.0

Adverse Benefit Determination: ERISA 29 CFR § 2560.503-1 Rules, Internal Appeals, and Independent Medical Review (IMR)

Regulatory guide to Adverse Benefit Determinations (ABDs) under ERISA (29 CFR 2560.503-1) and the ACA (45 CFR 147.136): mandatory notice elements, urgent/pre-service/post-service timelines, internal appeals, and binding Independent Medical Review (IMR).

Written and maintained by CASRAI Editorial Board

Published

On this page

Utilization review physicians, hospital revenue-integrity teams, and clinical trial patient navigators handling an adverse benefit determination (ABD) operate under strict federal procedural rules codified by the U.S. Department of Labor (DOL) and the Department of Health and Human Services (HHS). Under the Employee Retirement Income Security Act (ERISA) claims procedure regulation at 29 CFR § 2560.503-1 and the Affordable Care Act (ACA) internal/external appeal standards at 45 CFR § 147.136 (Public Health Service Act Section 2719), any partial or complete denial of healthcare coverage triggers mandatory clinical disclosure duties, statutory decision clocks, internal peer-review rights, and access to binding Independent Medical Review (IMR).

What Is an Adverse Benefit Determination Under ERISA and the ACA?

Under 29 CFR § 2560.503-1(m)(4) and 45 CFR § 147.136(a)(2)(i), an adverse benefit determination is defined broadly to prevent health plans or Third-Party Administrators (TPAs) from evading appeal rights by labeling a denial as an “administrative adjustment” or “partial payment.” Specifically, an ABD encompasses any of the following actions by a group health plan or health insurance issuer:

  • Denial, Reduction, or Termination of a Benefit: Any refusal to authorize or pay (in whole or in part) for a requested diagnostic test, inpatient admission, surgical procedure, or specialty drug during prospective, concurrent review, or retrospective utilization review.
  • Medical Necessity and Experimental/Investigational Exclusions: Any determination that a requested item, clinical trial routine care service, or genetic test is “not medically necessary,” “experimental,” “investigational,” or fails a step therapy (fail-first) protocol.
  • Eligibility and Network Determinations: Denials based on a participant’s or beneficiary’s eligibility to participate in a plan or application of out-of-network cost-sharing penalties.
  • Rescission of Coverage: Any cancellation or discontinuance of coverage that has a retroactive effect, except to the extent it is attributable to a failure to timely pay required premiums or contributions (45 CFR § 147.128).

Mandatory Notice Contents and Statutory Decision Timelines (29 CFR § 2560.503-1)

When a health plan issues an initial Adverse Benefit Determination, 29 CFR § 2560.503-1(g) and 45 CFR § 147.136(b)(2)(ii)(E) require the written or electronic notice to include: (1) sufficient information to identify the claim (date of service, provider, claim amount, and diagnosis/treatment codes upon request), (2) the specific reason(s) for the denial, including the plan’s denial code and its plain-language meaning, (3) reference to the specific plan provisions on which the determination is based, (4) if based on medical necessity or an experimental/investigational exclusion, either an explanation of the scientific or clinical judgment for the determination applying the terms of the plan to the claimant’s medical circumstances or a statement that such explanation will be provided free of charge upon request, and (5) a description of available internal appeals and external review processes.

Furthermore, under a growing body of state utilization review laws governing AI claim denials, an adverse determination based on medical necessity cannot be finalized solely by an automated algorithm; it must be reviewed and signed by a licensed physician or qualified healthcare professional.

Claim / Appeal Category Initial ABD Decision Deadline Claimant Filing Window for Internal Appeal Internal Appeal Decision Deadline
Urgent Care Claim (delay could seriously jeopardize life, health, or ability to regain maximum function) As soon as possible, ≤ 72 hours after receipt of claim (24 hours to request missing info) 180 calendar days following receipt of initial ABD notice As soon as possible, ≤ 72 hours after receipt of urgent appeal
Pre-Service Claim (prior authorization required before medical care is rendered) ≤ 15 calendar days (one 15-day extension if beyond plan control with prior notice) 180 calendar days following receipt of initial ABD notice ≤ 30 calendar days total (or 15 days per level in a 2-level plan)
Concurrent Care Extension (request to extend ongoing course of treatment) ≤ 24 hours before expiration if urgent and requested ≥24 hours prior; otherwise urgent/pre-service rules 180 calendar days (coverage must continue pending internal appeal of a reduced ongoing course of treatment) ≤ 72 hours (if urgent) or pre-service appeal timeline
Post-Service Claim (retrospective claim for care already rendered) ≤ 30 calendar days (one 15-day extension with notice before Day 30) 180 calendar days following receipt of initial ABD notice ≤ 60 calendar days total (or 30 days per level in a 2-level plan)

Note: For Medicare Advantage (42 CFR § 422.568 / CMS-0057-F beginning 2026) and Medicaid Managed Care (42 CFR § 438.210), CMS enforces stricter prior authorization decision windows of 72 hours for expedited requests and 7 calendar days for standard pre-service requests.

ERISA Claim Denial Appeals: Full and Fair Review Requirements

When submitting an ERISA claim denial appeal (supported by a structured Letter of Medical Necessity and appeal checklist), clinical teams should explicitly invoke four procedural rights guaranteed under 29 CFR § 2560.503-1(h) and 45 CFR § 147.136(b)(2):

  1. Free Access to the Complete Claim File and Internal Clinical Criteria: The claimant (or authorized treating physician) is entitled to receive, free of charge, copies of all documents, records, internal clinical policy bulletins (such as InterQual or MCG criteria subsets), and other information “relevant” to the claim—whether or not relied upon in making the initial denial.
  2. De Novo Review by an Unaffiliated Superior: The internal appeal review may not afford deference to the initial adverse benefit determination and must be conducted by an individual who is neither the individual who made the initial ABD nor the subordinate of that individual.
  3. Mandatory Consultation with a Appropriately Qualified Specialist (29 CFR § 2560.503-1(h)(3)(iii)): In deciding any appeal of an ABD that is based in whole or in part on a medical judgment (including whether a treatment is experimental, investigational, or not medically necessary), the fiduciary must consult with a healthcare professional who has appropriate training and experience in the field of medicine involved in the medical judgment (and who was not consulted in connection with the initial denial).
  4. Right to Respond to New or Additional Evidence Before Final Denial: Under 45 CFR § 147.136(b)(2)(ii)(C), before a plan can issue a Final Internal Adverse Benefit Determination based on any new or additional evidence or rationale considered, generated, or relied upon during the appeal, the plan must provide the claimant with the new evidence/rationale free of charge sufficiently in advance of the final decision date to give the claimant a reasonable opportunity to respond.

External Review in Health Insurance and Independent Medical Review (IMR)

If the health plan upholds its denial on internal appeal (or if the plan fails to strictly adhere to federal internal appeal rules, triggering “deemed exhaustion” under 45 CFR § 147.136(b)(2)(ii)(F)), the claimant has the statutory right to request binding external review health insurance adjudication—commonly known as Independent Medical Review (IMR):

  • Scope of External Review (45 CFR § 147.136(c)–(d)): Available for any Final Internal Adverse Benefit Determination that involves (a) medical judgment (including medical necessity, appropriateness, healthcare setting, level of care, effectiveness, or experimental/investigational determinations), (b) surprise billing / No Surprises Act cost-sharing protections, or (c) a rescission of coverage.
  • Filing Window and IRO Assignment: Claimants have at least 4 months after receipt of a Final Internal ABD to file an external review request. The review is assigned on a rotational basis to an accredited, conflict-free Independent Review Organization (IRO) certified by URAC or a state department of insurance.
  • De Novo Standard and Binding Effect: The IRO physician reviewer evaluates the clinical record, peer-reviewed medical literature, and specialty society guidelines de novo without being bound by the insurer’s internal proprietary coverage policy. The IRO must issue a written decision within 45 calendar days for standard external reviews or within 72 hours for expedited urgent external reviews. If the IRO overturns the denial, the health plan must immediately provide coverage or payment for the claim regardless of whether the plan intends to seek judicial review.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about Adverse Benefit Determination: ERISA 29 CFR § 2560.503-1 Rules, Internal Appeals, and Independent Medical Review (IMR)

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →